Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Mutant and wild-type isocitrate dehydrogenase 1 share enhancing mechanisms involving distinct tyrosine kinase cascades in cancer.

Chen D, Xia S, Wang M, Lin R, Li Y, Mao H, Aguiar M, Famulare CA, Shih AH, Brennan CW, Gao X, Pan Y, Liu S, Fan J, Jin L, Song L, Zhou A, Mukherjee J, Pieper RO, Mishra A, Peng J, Arellano M, Blum WG, Lonial S, Boggon TJ, Levine RL, Chen J.

Cancer Discov. 2019 Mar 12. pii: CD-18-1040. doi: 10.1158/2159-8290.CD-18-1040. [Epub ahead of print]

PMID:
30862724
2.

HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI.

Radoul M, Najac C, Viswanath P, Mukherjee J, Kelly M, Gillespie AM, Chaumeil MM, Eriksson P, Delos Santos R, Pieper RO, Ronen SM.

NMR Biomed. 2019 Feb;32(2):e4044. doi: 10.1002/nbm.4044. Epub 2018 Dec 18.

PMID:
30561869
3.

Neurofibromin knockdown in glioma cell lines is associated with changes in cytokine and chemokine secretion in vitro.

Wood MD, Mukherjee J, Pieper RO.

Sci Rep. 2018 Apr 11;8(1):5805. doi: 10.1038/s41598-018-24046-2.

4.

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.

Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper RO, Phillips JJ, Ronen SM.

Cancer Metab. 2018 Apr 3;6:3. doi: 10.1186/s40170-018-0178-3. eCollection 2018.

5.

Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.

Mukherjee J, Johannessen TC, Ohba S, Chow TT, Jones L, Pandita A, Pieper RO.

Cancer Res. 2018 Jun 1;78(11):2966-2977. doi: 10.1158/0008-5472.CAN-17-2269. Epub 2018 Mar 15.

PMID:
29545335
6.

2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.

Viswanath P, Radoul M, Izquierdo-Garcia JL, Ong WQ, Luchman HA, Cairncross JG, Huang B, Pieper RO, Phillips JJ, Ronen SM.

Cancer Res. 2018 May 1;78(9):2290-2304. doi: 10.1158/0008-5472.CAN-17-2926. Epub 2018 Jan 22.

PMID:
29358170
7.

Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process.

Ohba S, Mukherjee J, Johannessen TC, Mancini A, Chow TT, Wood M, Jones L, Mazor T, Marshall RE, Viswanath P, Walsh KM, Perry A, Bell RJ, Phillips JJ, Costello JF, Ronen SM, Pieper RO.

Cancer Res. 2016 Nov 15;76(22):6680-6689. doi: 10.1158/0008-5472.CAN-16-0696. Epub 2016 Oct 6.

8.

UBE2S, a novel substrate of Akt1, associates with Ku70 and regulates DNA repair and glioblastoma multiforme resistance to chemotherapy.

Hu L, Li X, Liu Q, Xu J, Ge H, Wang Z, Wang H, Wang Z, Shi C, Xu X, Huang J, Lin Z, Pieper RO, Weng C.

Oncogene. 2017 Feb 23;36(8):1145-1156. doi: 10.1038/onc.2016.281. Epub 2016 Sep 5.

PMID:
27593939
9.

Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.

Johannessen TA, Mukherjee J, Viswanath P, Ohba S, Ronen SM, Bjerkvig R, Pieper RO.

Mol Cancer Res. 2016 Oct;14(10):976-983. Epub 2016 Jul 18.

10.

Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.

Viswanath P, Najac C, Izquierdo-Garcia JL, Pankov A, Hong C, Eriksson P, Costello JF, Pieper RO, Ronen SM.

Oncotarget. 2016 Jun 7;7(23):34942-55. doi: 10.18632/oncotarget.9006.

11.

PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells.

Mukherjee J, Ohba S, See WL, Phillips JJ, Molinaro AM, Pieper RO.

Int J Cancer. 2016 Jul 1;139(1):99-111. doi: 10.1002/ijc.30041. Epub 2016 Mar 2.

12.

IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.

Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, Blough M, Luchman HA, Weiss S, Cairncross JG, Phillips JJ, Pieper RO, Ronen SM.

Cancer Res. 2015 Aug 1;75(15):2999-3009. doi: 10.1158/0008-5472.CAN-15-0840. Epub 2015 Jun 4.

13.

Metabolic reprogramming in mutant IDH1 glioma cells.

Izquierdo-Garcia JL, Viswanath P, Eriksson P, Chaumeil MM, Pieper RO, Phillips JJ, Ronen SM.

PLoS One. 2015 Feb 23;10(2):e0118781. doi: 10.1371/journal.pone.0118781. eCollection 2015.

14.

Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells.

Park I, Mukherjee J, Ito M, Chaumeil MM, Jalbert LE, Gaensler K, Ronen SM, Nelson SJ, Pieper RO.

Cancer Res. 2014 Dec 1;74(23):7115-24. doi: 10.1158/0008-5472.CAN-14-0849. Epub 2014 Oct 15.

15.

Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.

Izquierdo-Garcia JL, Cai LM, Chaumeil MM, Eriksson P, Robinson AE, Pieper RO, Phillips JJ, Ronen SM.

PLoS One. 2014 Sep 22;9(9):e108289. doi: 10.1371/journal.pone.0108289. eCollection 2014.

16.

Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.

Ohba S, Mukherjee J, See WL, Pieper RO.

Cancer Res. 2014 Sep 1;74(17):4836-44. doi: 10.1158/0008-5472.CAN-14-0924. Epub 2014 Jul 17.

17.

Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.

Chaumeil MM, Larson PE, Woods SM, Cai L, Eriksson P, Robinson AE, Lupo JM, Vigneron DB, Nelson SJ, Pieper RO, Phillips JJ, Ronen SM.

Cancer Res. 2014 Aug 15;74(16):4247-57. doi: 10.1158/0008-5472.CAN-14-0680. Epub 2014 May 29.

18.

Lactate dehydrogenase A silencing in IDH mutant gliomas.

Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, Pieper RO, Ronen SM, Weiss S, Luchman HA, Cairncross JG.

Neuro Oncol. 2014 May;16(5):686-95. doi: 10.1093/neuonc/not243. Epub 2013 Dec 22.

19.

Non-invasive in vivo assessment of IDH1 mutational status in glioma.

Chaumeil MM, Larson PE, Yoshihara HA, Danforth OM, Vigneron DB, Nelson SJ, Pieper RO, Phillips JJ, Ronen SM.

Nat Commun. 2013;4:2429. doi: 10.1038/ncomms3429.

20.

Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage.

Ito M, Ohba S, Gaensler K, Ronen SM, Mukherjee J, Pieper RO.

PLoS One. 2013 May 7;8(5):e62351. doi: 10.1371/journal.pone.0062351. Print 2013.

21.

Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma.

Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM, Pieper RO.

PLoS One. 2013;8(2):e57610. doi: 10.1371/journal.pone.0057610. Epub 2013 Feb 25.

22.

Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging.

Park I, Hu S, Bok R, Ozawa T, Ito M, Mukherjee J, Phillips JJ, James CD, Pieper RO, Ronen SM, Vigneron DB, Nelson SJ.

Magn Reson Med. 2013 Jul;70(1):33-9. doi: 10.1002/mrm.24434. Epub 2012 Jul 31.

23.

Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla.

Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel PS, James CD, Berger MS, Ronen SM.

Neuro Oncol. 2012 Aug;14(8):1050-61. doi: 10.1093/neuonc/nos126. Epub 2012 Jun 4.

24.

Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.

See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper RO.

Cancer Res. 2012 Jul 1;72(13):3350-9. doi: 10.1158/0008-5472.CAN-12-0334. Epub 2012 May 9.

25.

NPAS3 demonstrates features of a tumor suppressive role in driving the progression of Astrocytomas.

Moreira F, Kiehl TR, So K, Ajeawung NF, Honculada C, Gould P, Pieper RO, Kamnasaran D.

Am J Pathol. 2011 Jul;179(1):462-76. doi: 10.1016/j.ajpath.2011.03.044. Epub 2011 May 19.

26.

Downregulation of FIP200 induces apoptosis of glioblastoma cells and microvascular endothelial cells by enhancing Pyk2 activity.

Wang D, Olman MA, Stewart J Jr, Tipps R, Huang P, Sanders PW, Toline E, Prayson RA, Lee J, Weil RJ, Palmer CA, Gillespie GY, Liu WM, Pieper RO, Guan JL, Gladson CL.

PLoS One. 2011;6(5):e19629. doi: 10.1371/journal.pone.0019629. Epub 2011 May 13.

27.

Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.

Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper RO, Shannon K.

Cancer Res. 2011 Jan 1;71(1):106-15. doi: 10.1158/0008-5472.CAN-10-2732.

28.

Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma.

Waldron JS, Yang I, Han S, Tihan T, Sughrue ME, Mills SA, Pieper RO, Parsa AT.

J Clin Neurosci. 2010 Dec;17(12):1543-7. doi: 10.1016/j.jocn.2010.04.021. Epub 2010 Sep 6.

29.

Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.

Panner A, Crane CA, Weng C, Feletti A, Fang S, Parsa AT, Pieper RO.

Cancer Res. 2010 Jun 15;70(12):5046-53. doi: 10.1158/0008-5472.CAN-09-3979. Epub 2010 May 18.

30.

FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes.

Dai B, Pieper RO, Li D, Wei P, Liu M, Woo SY, Aldape KD, Sawaya R, Xie K, Huang S.

Cancer Res. 2010 Apr 1;70(7):2951-61. doi: 10.1158/0008-5472.CAN-09-3909. Epub 2010 Mar 23.

31.

Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion.

Han SJ, Ahn BJ, Waldron JS, Yang I, Fang S, Crane CA, Pieper RO, Parsa AT.

Neuroreport. 2009 Dec 9;20(18):1597-602. doi: 10.1097/WNR.0b013e32833188f7.

32.

A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.

Panner A, Crane CA, Weng C, Feletti A, Parsa AT, Pieper RO.

Cancer Res. 2009 Oct 15;69(20):7911-6. doi: 10.1158/0008-5472.CAN-09-1287. Epub 2009 Oct 6.

33.

Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function.

Crane C, Panner A, Pieper RO, Arbiser J, Parsa AT.

J Immunother. 2009 Jul-Aug;32(6):585-92. doi: 10.1097/CJI.0b013e3181a8efe6.

34.

The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma.

Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, Ramnarain DB, Xiao G, Saha D, Boothman DA, Zhao D, Bachoo RM, Pieper RO, Habib AA.

Cancer Res. 2009 Apr 1;69(7):2809-16. doi: 10.1158/0008-5472.CAN-08-4079.

35.

p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.

Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, Haas-Kogan DA, Vandenberg SR, Berger MS, James CD.

Cancer Res. 2008 Dec 15;68(24):10034-9. doi: 10.1158/0008-5472.CAN-08-1687.

36.

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer.

Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, Simko JP, Waldman FM, Pieper RO, Parsa AT.

Oncogene. 2009 Jan 15;28(2):306-12. doi: 10.1038/onc.2008.384. Epub 2008 Oct 13.

37.

S6K1 plays a key role in glial transformation.

Nakamura JL, Garcia E, Pieper RO.

Cancer Res. 2008 Aug 15;68(16):6516-23. doi: 10.1158/0008-5472.CAN-07-6188.

38.

Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas.

Baia GS, Stifani S, Kimura ET, McDermott MW, Pieper RO, Lal A.

Neoplasia. 2008 Jun;10(6):604-12.

39.

H-Ras increases urokinase expression and cell invasion in genetically modified human astrocytes through Ras/Raf/MEK signaling pathway.

Zhao Y, Xiao A, Dipierro CG, Abdel-Fattah R, Amos S, Redpath GT, Carpenter JE, Pieper RO, Hussaini IM.

Glia. 2008 Jun;56(8):917-24. doi: 10.1002/glia.20667.

40.

Increased expression of the glioma-associated antigen ARF4L after loss of the tumor suppressor PTEN. Laboratory investigation.

Chi JH, Panner A, Cachola K, Crane CA, Murray J, Pieper RO, James CD, Parsa AT.

J Neurosurg. 2008 Feb;108(2):299-303. doi: 10.3171/JNS/2008/108/2/0299.

PMID:
18240926
41.
42.

Glioma invasiveness responds variably to irradiation in a co-culture model.

Nakamura JL, Haas-Kogan DA, Pieper RO.

Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):880-6.

PMID:
17889268
43.

Contribution of Notch signaling activation to human glioblastoma multiforme.

Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L, Pieper RO.

J Neurosurg. 2007 Mar;106(3):417-27.

PMID:
17367064
44.

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.

Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK.

PLoS Med. 2006 Dec;3(12):e485.

45.

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.

Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO.

Nat Med. 2007 Jan;13(1):84-8. Epub 2006 Dec 10.

PMID:
17159987
46.

The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.

Kawaguchi T, Yamashita Y, Kanamori M, Endersby R, Bankiewicz KS, Baker SJ, Bergers G, Pieper RO.

Cancer Res. 2006 Dec 1;66(23):11331-40.

47.
48.

Intracranial microenvironment reveals independent opposing functions of host alphaVbeta3 expression on glioma growth and angiogenesis.

Kanamori M, Kawaguchi T, Berger MS, Pieper RO.

J Biol Chem. 2006 Dec 1;281(48):37256-64. Epub 2006 Oct 6.

49.

Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme.

Panner A, Parsa AT, Pieper RO.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1313-22. Review.

PMID:
17020463
50.

DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells.

Katayama M, Kawaguchi T, Berger MS, Pieper RO.

Cell Death Differ. 2007 Mar;14(3):548-58. Epub 2006 Sep 1.

Supplemental Content

Loading ...
Support Center